Emergent BioSolutions(EBS) The Motley Fool·2024-12-30 22:26Company Overview - Emergent BioSolutions (EBS) stock gained nearly 12% on the day following an analyst's initiation of coverage, contrasting with the S&P 500's 1% decline [2] - H C Wainwright's Raghuram Selvaraju initiated coverage with a buy recommendation and a price target of $15 per share, which is 62% higher than the stock's current level [3] - The company is well positioned to be a frontline player in potential future healthcare emergencies due to its diversified offerings [4][6] Business Segments - The company's vaccines business includes jabs for monkeypox and smallpox, with monkeypox recently highlighted as a potential global healthcare threat [1] - Emergent's Narcan opioid reversal spray is expected to continue experiencing heavy demand due to the ongoing opioid epidemic in the U S [5] Analyst Perspective - Raghuram Selvaraju views Emergent as well diversified across several medical segments with strong growth potential [5] - The analyst's positive outlook on the company's diversification makes the stock a worthy consideration for investment [6]